STOCK-BASED COMPENSATION (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
Schedule of stock-based compensation |
Total stock-based compensation expense related to all of our stock-based awards was as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
2023 |
|
2022 |
|
2021 |
Selling, general and administrative |
$ |
6,712 |
|
$ |
10,217 |
|
$ |
7,337 |
Research and development |
|
2,094 |
|
|
2,168 |
|
|
1,700 |
Restructuring charges |
|
— |
|
|
— |
|
|
449 |
Total stock-based compensation expense |
$ |
8,806 |
|
$ |
12,385 |
|
$ |
9,486 |
|
Schedule of option activity under equity incentive plans |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Options |
|
RSUs |
|
|
|
|
|
|
|
Weighted |
|
Weighted |
|
|
|
Weighted Average |
|
|
|
Shares Available |
|
Number of |
|
Average |
|
Intrinsic Value |
|
Number of |
|
Grant Date |
|
|
|
For Grant |
|
Shares |
|
Exercise Price |
|
(in thousands) |
|
Shares |
|
Fair Value |
|
Outstanding as of December 31, 2022 |
|
10,612,618 |
|
34,696,273 |
|
$ |
2.74 |
|
$ |
1,605 |
|
1,103,653 |
|
$ |
2.39 |
|
Authorized for grant |
|
5,019,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted |
|
(5,669,944) |
|
3,671,800 |
|
$ |
1.69 |
|
|
|
|
1,387,600 |
|
$ |
1.80 |
|
Exercised/Released |
|
— |
|
(50,161) |
|
$ |
0.97 |
|
|
|
|
(435,006) |
|
$ |
2.32 |
|
Cancelled and forfeited |
|
3,908,921 |
|
(4,199,147) |
|
$ |
3.29 |
|
|
|
|
(190,356) |
|
$ |
2.20 |
|
Outstanding as of December 31, 2023 |
|
13,871,295 |
|
34,118,765 |
|
$ |
2.56 |
|
$ |
1,453 |
|
1,865,891 |
|
$ |
1.98 |
|
Vested and expected to vest as of December 31, 2023 |
|
|
|
31,373,765 |
|
$ |
2.55 |
|
$ |
1,349 |
|
|
|
|
|
|
Exercisable as of December 31, 2023 |
|
|
|
24,378,890 |
|
$ |
2.70 |
|
$ |
403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of stock options by exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
Options Exercisable |
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
|
|
|
|
Number of |
|
Remaining Contractual |
|
Weighted-Average |
|
Number of |
|
Weighted-Average |
Exercise Price |
|
Shares |
|
Life (in years) |
|
Exercise Price |
|
Shares |
|
Exercise Price |
$0.90 - $1.87 |
|
6,712,896 |
|
8.61 |
|
$ |
1.43 |
|
1,991,518 |
|
$ |
1.44 |
$1.96 - $2.11 |
|
5,063,237 |
|
4.44 |
|
$ |
2.03 |
|
5,063,237 |
|
$ |
2.03 |
$2.14 - $2.40 |
|
3,940,279 |
|
2.89 |
|
$ |
2.26 |
|
3,717,256 |
|
$ |
2.26 |
$2.42 - $2.42 |
|
5,816,323 |
|
6.81 |
|
$ |
2.42 |
|
3,794,160 |
|
$ |
2.42 |
$2.44 - $3.54 |
|
6,852,637 |
|
5.14 |
|
$ |
3.16 |
|
4,473,712 |
|
$ |
3.06 |
$3.59 - $4.49 |
|
5,542,956 |
|
3.95 |
|
$ |
3.97 |
|
5,215,904 |
|
$ |
3.99 |
$4.50 - $4.50 |
|
190,437 |
|
7.29 |
|
$ |
4.50 |
|
123,103 |
|
$ |
4.50 |
$0.90 - $4.50 |
|
34,118,765 |
|
5.56 |
|
$ |
2.56 |
|
24,378,890 |
|
$ |
2.70 |
|
Employee Stock Option [Member] |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
Summary of weighted-average assumptions relating to options granted |
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2023 |
|
2022 |
|
2021 |
|
Risk-free interest rate |
|
3.9 |
% |
2.6 |
% |
1.0 |
% |
Expected term (in years) |
|
6.8 |
|
6.3 |
|
6.4 |
|
Dividend yield |
|
0.0 |
% |
0.0 |
% |
0.0 |
% |
Expected volatility |
|
84.0 |
% |
74.8 |
% |
70.5 |
% |
|
Purchase Plan |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan |
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2023 |
|
2022 |
|
2021 |
|
Risk-free interest rate |
|
* |
|
3.1 |
% |
* |
|
Expected term (in years) |
|
* |
|
1.3 |
|
* |
|
Dividend yield |
|
* |
|
0.0 |
% |
* |
|
Expected volatility |
|
* |
|
121.0 |
% |
* |
|
Weighted average grant date fair value (dollar per share) |
|
* |
|
$0.78 |
|
* |
|
|